Business Description
Sagittarius Life Science Corp
NAICS : 325412
SIC : 2834
No. 3, Park Street, 6th Floor, Nangang District, Taipei, TWN
Compare
Compare
Traded in other countries / regions
3205.Taiwan
Description
Sagittarius Life Science Corp is a Taiwan based company engaged in operating as a biotechnology and pharmaceutical company. Its business activity is to develop Chinese herbal medicines and supplements for the treatment of bone fractures, osteoporosis, wound healing and skin care.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 14.23 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.35 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 10.77 | |||||
| Beneish M-Score | -2.74 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.9 | |||||
| 3-Year EBITDA Growth Rate | 7.2 | |||||
| 3-Year EPS without NRI Growth Rate | 1.7 | |||||
| 3-Year FCF Growth Rate | 13.4 | |||||
| 3-Year Book Growth Rate | -13.3 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.05 | |||||
| 9-Day RSI | 57.82 | |||||
| 14-Day RSI | 61.04 | |||||
| 6-1 Month Momentum % | 79.88 | |||||
| 12-1 Month Momentum % | 71.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.39 | |||||
| Quick Ratio | 4.02 | |||||
| Cash Ratio | 3.49 | |||||
| Days Inventory | 27.44 | |||||
| Days Sales Outstanding | 27.89 | |||||
| Days Payable | 43.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | -100 | |||||
| 3-Year Average Share Buyback Ratio | 0.2 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 16.24 | |||||
| Operating Margin % | -15.69 | |||||
| Net Margin % | -14.9 | |||||
| ROE % | -16.19 | |||||
| ROA % | -12.64 | |||||
| ROIC % | -36.38 | |||||
| ROC (Joel Greenblatt) % | -60.41 | |||||
| ROCE % | -15.41 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shiller PE Ratio | 85.91 | |||||
| PS Ratio | 3.05 | |||||
| PB Ratio | 3.52 | |||||
| Price-to-Tangible-Book | 3.51 | |||||
| EV-to-EBIT | -16.82 | |||||
| EV-to-EBITDA | -22.87 | |||||
| EV-to-Revenue | 2.53 | |||||
| EV-to-FCF | -28.29 | |||||
| Price-to-Projected-FCF | 4.75 | |||||
| Price-to-Median-PS-Value | 1.25 | |||||
| Price-to-Net-Current-Asset-Value | 6.38 | |||||
| Price-to-Net-Cash | 9.07 | |||||
| Earnings Yield (Greenblatt) % | -5.95 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 574.486 | ||
| EPS (TTM) (NT$) | -2.62 | ||
| Beta | -0.28 | ||
| Volatility % | 95.68 | ||
| 14-Day RSI | 61.04 | ||
| 14-Day ATR (NT$) | 3.639913 | ||
| 20-Day SMA (NT$) | 51.875 | ||
| 12-1 Month Momentum % | 71.27 | ||
| 52-Week Range (NT$) | 20.65 - 58.7 | ||
| Shares Outstanding (Mil) | 32.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sagittarius Life Science Corp Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||